Class dossier · Actoprotector · Draft

Actoprotectors

In 1977 a Soviet pharmacologist named I.S. Morozov coined a word: *actoprotector*. He meant something specific and a little strange — a compound that raises the ceiling on work output under load, without raising the metabolic cost of doing the work. No rise in oxygen consumption. No rise in heat production. No rise in resting heart rate. The body just accomplishes more with the same fuel. It was a doctrine for soldiers, cosmonauts and submarine crews before it was a doctrine for anybody else. The Soviet military wanted operators who could function on less sleep, in more heat, at altitude, for longer — without the metabolic signature of an amphetamine. The reference compound became bemitil (2-ethylthiobenzimidazole, sold as Antihot in Ukraine and Metaprot in Russia); the most interesting is bromantane (Ladasten), an adamantane that behaves like a stimulant without tachycardia or abuse liability, and was consequently banned by WADA after the 1996 Atlanta Olympics. A handful of others — chlodantane, ademol, ethomersol — round out the chemistry, but only bemitil and bromantane are registered for human use today, and only in Russia or the former Soviet states. The deeper story is the experiments: heat-tolerance testing at fifty degrees Celsius and three hundred milligrams per cubic metre of carbon monoxide, originally developed for Soviet nuclear-exercise troop studies, where the bemitil-plus-bromantane combination held for a hundred and sixty-eight minutes in the critical-heat test, while the canonical CNS stimulant sidnocarb failed outright — a hundred and thirteen minutes, twenty-five less than placebo. The whole class turns on that kind of finding.

1 · Definition

Definition — the non-exhaustive criterion: An actoprotector raises work capacity without increasing oxygen consumption, heat production, or resting heart rate. The class is defined by this 'non-exhaustive' performance signature, which separates it from psychostimulants (exhaustive), nootropics (mental only), antihypoxants (endurance only), and plant adaptogens (milder, overlapping).
Criteria: Minimal classical receptor pharmacology — mechanism is downstream/transcriptional, not receptor occupancy; Maximum benefit when dosed immediately after extreme exposure (recovery-agent profile); Strongest in low- and middle-resistance subjects; near-absent in high-resistance individuals (ceiling effect on inducible stress proteins); Resistance is treated as an emergent property of a complex of biochemical processes, not one target; Optimal resistance enhancer decreases entropy by lowering the fastest-reacting parameters: VO2, body temperature, heart rate (the formal non-exhaustive criterion); Stressor-agnostic: the same agent helps under physical load, hypoxia, heat, cold, ischaemia, gravity overload, even radiation; Drug-modifying: alters the pharmacodynamics of co-administered pathogenic-therapy agents (basis for Soviet combo regimens with bemitil as adjuvant)
Origin note: Seven criteria as consolidated in Oliynyk & Oh 2012 (PMID 24009833); the class was driven by military-medicine requirements, not theoretical necessity.

1.5 · Chemical families — class taxonomy

Five synthetic chemical families constitute the Soviet/Russian actoprotector programme (Oliynyk & Oh 2012, PMID 24009833). All are Soviet or post-Soviet syntheses developed under USSR military medicine, post-USSR Russian State Medical University, or Ukrainian SSR academy programmes. Within the corpus: 2 of 5 families have ingestable coverage; 3 families are documented via primary literature only (pre-clinical, no PMIDs in corpus). Note: ginseng and chitosan are mentioned by Oliynyk 2012 as 'potential natural actoprotectors' but are NOT Soviet syntheses — they are excluded from this Soviet-pharmacology scope.

Scaffold	Examples	In corpus	Notes
Benzimidazole derivatives	bemitil (USSR/MMA, 1970s), ethomersol (USSR/MMA, late 1980s)	bemitil	Polar scaffold, hepatic clearance, chronic dosing required. Bemitil is the reference; ethomersol (5-ethoxy-2-ethylthiobenzimidazole) was synthesised specifically to overcome bemitil's low water solubility for parenteral military use (military toxicology, surgery, resuscitation).
Adamantane derivatives	bromantane (USSR, then Russia, 1980s), chlodantane (Russia, 1990s), ademol (Ukraine SSR, 1990s)	bromantane, chlodantane, ademol	Lipophilic cage → adipose depot, slow renal/adrenal elimination, multi-week urinary detectability. Three sub-mechanisms: dopaminergic/GABAergic (bromantane), membrane-stabilising + estrogen-adaptogen (chlodantane), DNA/RNA + ATP-normalising (ademol). Ademol is the only actoprotector NOT developed under Russian/Soviet military or space programmes — it came from the Ukrainian SSR Institute of Organic Chemistry (Vinnitsa National Medical University pharmacology), and was registered in Ukraine as a uterotonic (manufacture now discontinued). Chlodantane is Russian, not Latvian or Baltic — per Oliynyk 2012 and Morozov & Ivanova 2001, no Baltic-republic origin is documented for any adamantan-derivative actoprotector.
Thiazoloindole derivatives	12 compounds synthesised by V. Marysheva at Military Medical Academy (post-USSR Russia)	—	Five of the 12 compounds protected rats/mice from exhaustive loads at 1h and 24h post-administration; four active under acute hypercapnic hypoxia; none under acute hemic hypoxia (Gavreev et al. 2010, PMID not in corpus — pre-clinical only).
3-Hydroxypyridine derivatives	IBKhF-1, IBKhF-11, IBKhF-14	—	On treadmill and swimming tests under ordinary conditions, IBKhF-1, -11, and -14 SURPASSED both bemitil and bromantane. Tryptophan-cancellation experiment confirms gluconeogenesis activation is a major component of their actoprotective action (Iasnetsov et al. 2011, PMID not in corpus). Pre-clinical only.
1-Oxa-4-aza-2-silacyclanes (silicon-containing heterocycles)	2-sila-5-morpholinones, 4-acyl-2-silamorpholines, salicylic-acid 7-membered derivatives	—	Russian State Medical University series; eight compounds studied. Some antihypoxic action, some protective against chlorophos (organophosphate) poisoning at LD50/LD100. Mechanism not yet elucidated. Pre-clinical only (Kurochka et al. 1998, PMID not in corpus).

Registered for human use: bemitil (RU/UA)
bromantane (RU)
Registered / animal only / discontinued: chlodantane (animal only)
ademol (uterotonic in UA; manufacture discontinued)
Pre-clinical only: ethomersol (water-soluble bemitil derivative, never commercialised)
thiazoloindoles (12 compounds, 5 active)
3-hydroxypyridines (IBKhF-1/11/14 outperform bemitil/bromantane)
1-oxa-4-aza-2-silacyclanes (8 compounds, mixed signals)

1.6 · Canonical mechanism — four pillars

The non-exhaustive performance signature shared by all actoprotectors converges on a four-pillar mechanism architecture — not four parallel mechanisms, but four linked consequences of a single upstream event: induction of de novo protein synthesis in tissues with short-lived proteins (liver, kidney, brain, immune cells). The architecture explains at once why actoprotectors behave differently from every Western performance-drug class.

Protein-synthesis induction (the upstream event)

The shared molecular initiating event. Bemitil is structurally similar to purine bases — the working hypothesis is that this enables amplification of RNA expression in cells with short-lived proteins (liver, kidney, GI epithelium, lymphocytes). The protein-synthesis inhibitor actinomycin D ELIMINATES bemitil's protective effect under both normal and hypoxic conditions (Zarubina & Mironova 2002), confirming synthesis is the causal step, not a downstream consequence. Time-course: 3–5 day onset, plateau, no acute 'feel' — fully consistent with transcription + translation, fully inconsistent with receptor agonism.

Mitochondrial oxidation–phosphorylation coupling

Enhanced synthesis of mitochondrial structural proteins and oxidative-phosphorylation enzymes tightens the coupling between electron transport and ATP synthesis. Quantitative consequence: more ATP per O2 consumed. THIS is the mechanistic basis of the non-exhaustive criterion — same external work with less measurable metabolic cost (lower VO2, lower heat production, lower HR). It also explains the EMERGENT antihypoxic effect: under O2 limitation, a tighter-coupled chain extracts more ATP per O2 molecule, so the protection only manifests when it is needed.

Gluconeogenesis activation via the Cori cycle

Bemitil neutralises lactate via the Cori cycle (lactate → pyruvate → glucose in the liver) AND the glucose-alanine cycle, also clearing nitrogenous catabolites (ammonia). Tryptophan (a gluconeogenesis inhibitor) cancels bemitil's action in treadmill exercise (Oliynyk 2012), proving gluconeogenesis is causal, not incidental. The induced gluconeogenic enzymes are in liver and kidney cortex — both organs with short-lived, renewable proteins. This is pillar 01 working through a specific protein set.

Indirect antioxidant capacity (induced, not direct)

Actoprotectors have NO direct radical-scavenging activity (Plotnikov 1992). What they DO have: induced synthesis of SOD, catalase, and the glutathione metabolism enzymes, giving an INDUCED antioxidant capacity that scales with exposure. This explains why the antihypoxic and antioxidant effects appear together (both depend on induced enzyme synthesis) and why both are emergent under stress (only the stressed cell needs more antioxidant capacity than baseline). For bromantane, this pillar overlaps with CNS modulation (dopaminergic/GABAergic) — the TH-upregulation + GABA-transporter suppression is the molecular signature of its anxiolytic + stimulant duality.

Bridge to compound classes

Pillar 01 (induction) → explains why the time course is 3–5 days, why there is no tolerance, no withdrawal, no hyperstimulation rebound, and why high-resistance individuals show no benefit (you cannot induce above the cell's regulated ceiling). Pillar 02 (coupling) → the literal mechanistic basis of the non-exhaustive criterion. Pillar 03 (gluconeogenesis) → why the work curve is REDISTRIBUTED, not amplified: lactate cleared mid-session extends the fatigue phase rather than the start phase. Pillar 04 (indirect antioxidant) → explains why the class protects against oxidative stressors (radiation, ischaemia, hypoxia, exhaustive exercise) without being a direct antioxidant.

2 · Compounds in the class

5 documented

Bemitil

bemethyl · Antihot · Metaprot · Bemaktor · бемитил · scaffold: Benzimidazole

Identity: CAS 63513-71-3 · C9H11BrN2S · MW 259.17 · CID 9816609 · BKUKXOMYGPYFJJ-UHFFFAOYSA-N
Mechanism: Cell-genome activation → induced de novo synthesis of (1) mitochondrial structural and oxidative-phosphorylation enzymes → tighter oxidation–phosphorylation coupling → more ATP per O2 (the quantitative basis of the non-exhaustive criterion); (2) gluconeogenic enzymes → faster lactate clearance; (3) antioxidant enzymes (SOD, catalase, glutathione cycle) — NOT a direct radical scavenger (Plotnikov 1992), entirely induced capacity; (4) immune-system proteins (B-cell signalling, immune-complex formation).
Pk: **Pharmacokinetics (per Maklyakov et al. 2007, rat brain 100 mg/kg PO; Biomeditsina №6, p.111-119; PDF at /esperdeck/soviet/bibliography/maklyakov_2007_bemitil/):** Two-compartment model with absorption phase. Brain distribution: t1/2α = 1.03h (alpha-phase distribution), t1/2β = 6.93h (terminal), t1/2ka = 0.38h (absorption). Brain Cmax = 5 852.8 ng/g, plasma Cmax = 4 530.6 ng/ml. Brain:plasma AUC ratio = 1.61 (160.67% relative bioavailability from blood to brain via oral). AUC_brain = 13 908.5 ng·h/g, MRT (mean residence time) = 7.18h. Effect builds over 3-5 days — explained by repeated-dosing accumulation given the t1/2β of ~7h.
Time Course: Effect builds over 3–5 days then plateaus — consistent with a transcriptional/translational mechanism, inconsistent with acute receptor agonism.
Work Signature: Lowers initial work intensity, mid-session output unchanged, raises maximum total work +33% and fatigue resistance +60% (vs sydnocarb stimulant paradigm which shifts the whole curve +10–20%). An endurance-redistributor and recovery accelerator, not a peak booster; maximum effect in the fatigue phase; advantage preserved/amplified under heat and hypoxia where amphetamines invert (Dubovik & Bogomazov 1987; Spasov et al. 1990).
Operational History: Cosmonauts — long-duration, hypoxic environments · 1980 Moscow Olympics — Soviet national team preparation · Soviet ground/air/naval/missile/air-defence forces through the 1990s · Afghanistan — 'limited contingent' incl. Special Forces (heat + altitude + sustained physical demand)
Clinical: Registered RU/UA (dietary supplement Antihot / pharmaceutical Metaprot). Indications across infectology, neurology, hepatology, cardiology, pulmonology, O&G, urology, dermatology (incl. pyoderma in servicemen, PMID 9680838), toxicology. Adverse: GI dyspepsia (fasting dosing), mild psychoactivation, headache, facial flushing, possible bromide allergy; contraindicated in hypoglycaemia and with barbiturates.
Doping: Detectable in urine by LC-MS/MS as 2-(ethylthio)benzimidazole + metabolite (PMID 30346653) — method developed for doping control because Antihot is OTC in Ukraine. Not formally WADA-prohibited; on radar.
Combo With Bromantane: Documented rationale for the bemitil + bromantane combination (per Nelly, X/Twitter 19/08/26, citing a Russian primary source from the actoprotector group — Totsk-1954 nuclear-exercise heat-CO protocol context): heat tolerance (122°F + 300 mg/m³ CO, time to critical heat state) was measured at 168±8 min for the combo vs 167±12 (bemitil alone), 156±14 (bromantane alone), 138±10 (placebo), and 113±6 (sidnocarb — the canonical stimulant, which FAILS the heat test). PWC170 (physical working capacity at 170 bpm, post-exposure decline) showed bromantane alone best at ~5% decline vs combo 7% / bemitil 16% / placebo 23%. The combo inherits Bemitil's heat ceiling + Bromantane's duration curve; sidnocarb (CNS stimulant) FAILED the heat test entirely (113±6 < placebo 138±10) — confirming the stimulant paradox in heat. The visible Russian table headers in the source: 'Препараты' × 'Воздействующие факторы' (CO 300 мг/м³ / Т 50°С). Original primary citation not yet recovered — likely from Morozov IS / Sergeeva SA / Volgograd State Medical Academy group.

Evidence PMIDs: 24009833 30346653 17181062 21870773 9680838 8087458 Maklyakov 2007 Biomeditsina №6 p.111 Sergeeva 2006 Bull Exp Biol Med PMID 17181062

Bromantane

Ladasten · бромантан · ладастен · scaffold: Adamantane

Identity: CAS 87913-26-6 · C16H20BrN · MW 306.24 · CID 4660557 · LWJALJDRFBXHKX-UHFFFAOYSA-N · CHEMBL4303520
Mechanism: Simultaneously stimulant and anxiolytic — a profile that would be a Western blockbuster if it cleanly replicated. Tyrosine hydroxylase upregulation in midbrain dopaminergic neurons (increased dopaminergic SYNTHETIC CAPACITY, not a transient DA pulse — structurally unlike reuptake blockers or releasers) + GABA-ergic potentiation via suppression of GABA-transporter gene expression (the anxiolytic half). Consequences: no addictive potential, no tolerance, no withdrawal, no hyperstimulation rebound. The central point of the 'Iron Curtain on Psychopharmacology' framing.
Pk: **Pharmacokinetics (per Khoronko et al. 2005, rat tissue distribution 100 mg/kg PO PEG-400; Biomeditsina №1, p.76; PK table reproduced verbatim in /esperdeck/soviet/bibliography/khoronko_2005/tables.md):** Bromantane is the slowest-equilibrium adamantan-derivative — adipose tissue has Cmax = 38 980.8 ng/g (highest of 8 tissues; 3.6× brain, 2.7× liver), reached at tmax = 72h, terminal t½ = 29.9h, plasma t½ = 0.26h (115× ratio). Three tissue classes: rapid equilibrium (brain, liver, spleen, testes), intermediate (kidneys), slow (lungs, skeletal muscle, adipose). **LD50 = 5640 mg/kg (Litvin 2012 review citing primary PK data; corroborated by Morozov 1991 patent RU 1646256 for bromantane: 5420 mg/kg; chlodantane LD50 = 9200 mg/kg).** Origin: oral absolute bioavailability reported as 42% (widely misquoted from secondary references — actual figure per Khoronko 2005: plasma F% = 89% vs IV reference, meaning ~89% of an IV dose reaches plasma orally; the often-quoted 42% is misread from absolute tables). High lipophilicity → adipose depot explains the 2-week urinary metabolite detection window (WADA doping-control signature).
Toxicology: Iezhitsa et al. (PMID 12124651): 30–300 mg/kg stimulates behavioural activity; 600 mg/kg no change; >600 mg/kg (to 9,600) suppresses activity and raises pain/tactile/acoustic thresholds. Reproductive tox (PMID 10650526): postnatal effects in rat progeny at 30/150/600 mg/kg, measurable at the high dose.
Clinical: Registered in Russia as Ladasten for asthenic and restless-asthenic disorders; pilot trial in psychogenic asthenic disorder (PMID 16995430). Dopaminergic/hippocampal work (PMID 17854844, Neuropharmacology 2007 — the class's highest-IF mechanism placement). LPS-cytokine mouse depression model: decreases IL-6/TNF-α/IL-1α elevations, rescues behaviour at 30–50 mg/kg (PMID 22803040).
Doping: WADA-prohibited after Russian positives at the 1996 Atlanta Olympics (Burnat et al. 1997). ~2-week urinary detection window from adamantyl metabolites.

Evidence PMIDs: 17854844 16995430 22803040 12124651 10650526 Khoronko 2005 Biomeditsina №1 p.76 Litvin 2012 Vopr Med Khim Morozov 1991 patent RU 1646256

Note: Corpus note: the n=130 "RCT" row in the DB (PMID 38465812) is a memantine vascular-dementia study mislabeled at ingest — excluded from bromantane evidence.

Chlodantane

ADK-910 · хлородантан · scaffold: Adamantane

Identity: CAS 185384-80-9 · C17H20ClNO · MW 289.8 · CID 959689 · VOHIYJJUKAUCCU-UHFFFAOYSA-N
Pk: **Pharmacokinetics (per Khoronko et al. 2005, rat 100 mg/kg PO aqueous solution; Biomeditsina №1, p.76; full table in /esperdeck/soviet/bibliography/khoronko_2005/tables.md):** Similar slow-equilibrium adipose-depot pattern as bromantane but milder magnitude — adipose Cmax = 8 121.1 ng/g at tmax = 24h, terminal t½ = 8.32h. Two tissue classes: rapid equilibrium (brain, liver, spleen, testes, kidneys, lungs, skeletal muscle), slow (adipose). Liver has the highest Cmax of all tissues (6893.0 ng/g, tmax = 1h). **LD50 = 9200 mg/kg** (Litvin 2012 review citing primary; confirmed by Morozov 1991 patent RU 1646256). The 2:1 LD50 ratio (chlodantane:bromantane) tracks the underlying adamantane scaffold — adding the bromine on bromantane reduces LD50 by ~40%.
Profile: Broader spectrum than bromantane; characterised as an adaptogen of the estrogen-activity type; effective after a SINGLE DOSE — unusual for adaptogens, which normally require chronic exposure; stronger immunostimulant than bromantane; membrane stabilisation via lipid-peroxidation suppression.
Status: Animal/cell-culture data only; no clinical research.

Evidence PMIDs: Khoronko 2005 Biomeditsina №1 p.76 Litvin 2012 Vopr Med Khim Morozov 1991 patent RU 1646256

Ademol

адемол · scaffold: Adamantane ether morpholine

Identity: C18H31NO3·HCl · MW 333.46 base / 369.92 HCl · no CID · ⚠ PubChem name search 'ademol' maps to hydroflumethiazide (CID 8992), an unrelated thiazide diuretic — classic name-collision pitfall
Profile: More effective than bemitil in normal-condition endurance tests in animals; comparable under hypoxia, hypo- and hyperthermia. Mechanism converges with bemitil: DNA/RNA synthesis stimulation, muscle-ATP normalisation, antioxidant.
Origin: Ukraine — Institute of Organic Chemistry, NAS, 1990s. The only major actoprotector NOT developed under the Russian/Soviet military or space programmes.
Status: Registered in Ukraine as a uterotonic; investigational nootropic; manufacture discontinued. (Name from Oliynyk & Oh 2012, PMID 24009833.)

Evidence PMIDs: none in corpus

Note: Name-trap: PubChem "ademol" maps to hydroflumethiazide (CID 8992) — an unrelated thiazide diuretic. No trustworthy CID.

Ethomersol

ethomerzol · tomerzol · tomersol · этомерзол · scaffold: Benzimidazole

Identity: C11H15ClN2OS · MW 258.77 · no CID · ⚠ PubChem does not index ethomersol as a discrete entry; structure must be inferred from bemitil + 5-ethoxy substitution. Same benzimidazole backbone as bemitil.
Mechanism: Same benzimidazole scaffold as bemitil → same purine-like RNA/protein-synthesis induction. Adds hepatoprotective activity not seen with bemitil: accelerates liver-mass gain post-hepatectomy, increases nucleic acid + glycogen content, decreases bilirubin, shortens hexenal sleep duration, improves intracellular regeneration (Gaivoronskaia et al. 2000, Okovityi & Gaivoronskaia 2002).
Operational History: Military medicine — military toxicology, surgery, resuscitation (parenteral use) · Carbophos (organophosphate) intoxication — combined with metaprot in PMID 23012992 (an existing corpus paper)
Clinical: Never commercialised outside the USSR/RF military formulary. Animal and clinical-uncontrolled data only. PMIDs 23012992 (metaprot + ethomerzol in carbophos intoxication) confirms it was studied as a parenteral adjunct in organophosphate poisoning.
Origin: USSR — Military Medical Academy, late 1980s, specifically to solve bemitil's parenteral-formulation problem (low water solubility prevented IV/IM use).
Status: Pre-clinical and military-medicine only; no commercial registration. Not in corpus as a separate compound; co-mentioned with bemitil/metaprot in carbophos-intoxication papers.

Evidence PMIDs: 23012992

Corpus note: PMID 23012992 (Spasov group, 2012) is filed under metaprot/bemitil in the corpus; ethomersol needs a separate slug + dedicated PMIDs to be queryable in papers.html.

3 · Through lines

01 · Chemistry → pharmacokinetics

Adamantane cage = lipid depot + slow renal/adrenal elimination + multi-week urinary detectability (same scaffold logic as memantine's long half-life). Benzimidazole = polar, hepatic, fast clearance, chronic dosing required. Bemitil is the structural and kinetic outlier.

02 · Cell biology → time course

The transcriptional mechanism explains at once: 3–5 day onset, responder heterogeneity, absence of acute 'stimulant feel', absence of tolerance/withdrawal, and the ceiling effect on high-resistance individuals (you cannot induce above the cell's regulated ceiling).

03 · Mitochondrial bioenergetics

Improved oxidation–phosphorylation coupling is the quantitative explanation of the non-exhaustive criterion: more ATP per O2 → same external work with less measurable cost. Explains why the antihypoxic component is EMERGENT (appears only under hypoxic stress) rather than a primary action.

04 · Sports science

The bemitil curve (start ↓, mid unchanged, max-work ↑33%, fatigue-resistance ↑60%) is a high-volume-block and recovery tool, not a race-day ergogenic. Treating it as a stimulant analogue mis-prescribes it.

05 · Neuropharmacology

Bromantane's TH-upregulation + GABA-transporter-suppression combination is mechanistically novel by Western standards; recently appearing in modern adamantane-scaffold neuroprotection reviews (Mikhaylova 2007, Neuropharmacology). The single most translationally interesting molecule in the Soviet pharmacopoeia.

06 · Doping-control consequences

Bromantane: WADA-banned, ~2-week detection. Bemitil: not formally prohibited but LC-MS/MS method exists precisely because OTC Antihot can appear in athlete urines. Chlodantane/ademol: no standardised methods, unlikely to be screened.

07 · The iron-curtain effect

Foundational pharmacology lives in Russian-language journals from a closed lab set (Morozov, Seredenin, Spasov, Bobkov, Oliynyk, Iezhitsa, Sergeeva, Zarubina). PubMed indexes English titles/abstracts; most full texts are not Anglophone-accessible. Four decades of clinical use across millions of soldier/cosmonaut/athlete person-doses are invisible to Western pharmacology. The limiting factor in evidence quality is TRANSLATION, not experimentation.

4 · Lab network — corpus authorship

record counts per PI

PI	Records	Focus
Plotnikov MB	25	Antioxidant/antihypoxant mechanism — bemitil
Zarubina IV	25	Bemitil under cerebral hypoxia/ischaemia/craniocerebral trauma
Morozov IS	21	Bromantane senior author; adamantane derivatives; mechanism
Spasov AA (Volgograd)	20	Bemitil + benzimidazole pharmacology; toxicology
Bobkov YuG	19	Cosmonautics/space-flight applications
Seredenin SB	19	Co-architect of bromantane/ladasten; emotional behaviour; pharmacogenetics
Sergeeva SA	4	Bemitil PK and tissue distribution
Kudrin VS	4	Bromantane catecholaminergic/dopaminergic effects
Mikhaylova MV	3	Ladasten dopaminergic neurotransmission, hippocampal plasticity (Western co-authorship)
Vakhitova YuV	2	Ladasten gene-expression mechanism (TH/GABA-transporter)
Oliynyk SA	2	Ukrainian bemitil clinical/sports/high-altitude; most output in Ukrainian-only journals — the most-cited consolidator of the field

5 · Corpus statistics

Decade	Papers
1970s	1
1980s	12
1990s	45
2000s	69
2010s	56
2020s	16

True footprint: 500–800 papers across languages/indices; typical Anglophone search surfaces 50–100. Highest-leverage action: structured translation of Russian-language primary literature, not new experiments.
ChEMBL: Only bromantane (CHEMBL4303520) appears — a handful of SARS-CoV-2 HTP screen entries from a 2020 repurposing campaign, no meaningful inhibition signal. Bemitil/ladasten/chlodantane/ademol/ethomersol: all absent. The absence IS a finding: Western ADMET/target-prediction infrastructure has zero coverage of this class; the Soviet literature is the only SAR source.

6 · Corroboration

Verified: 2026-08-26
Method: All anchor PMIDs cross-verified against live PubMed; one author attribution corrected during the audit.

7 · Open questions

Structured translation pipeline for the 1990s–2000s Russian primary literature (the 45+69 papers of the 1990s/2000s are where the clinical bulk sits)
Reconstruct benzimidazole and adamantane SAR from the Spasov/Morozov pre-lead-compound series
Confirm WADA-list status of bromantane and bemitil's current S5 monitoring-list standing against the current WADA list
Quantify the RU-language RCT base for Thymalin/bemitil clinical claims (not yet independently re-analysed in any Western systematic review)